Antitumor agent-122

Antitumor agent-122 是一种高效多靶点抗肿瘤剂,通过诱导铁死亡 (Ferroptosis)、自噬 (Autophagy)、凋亡 (Apoptosis) 和细胞周期阻滞 (Cell cycle arrest) 等机制发挥抗肿瘤作用:在铁死亡通路中,它可抑制 GPX4 表达并上调 FACL4 表达,增加细胞内脂质过氧化及亚铁离子水平;在自噬通路中,它通过抑制 AKT/mTOR 信号通路诱导自噬;在凋亡和细胞周期通路中,它将细胞阻滞于 G1/S 期,进而促进线粒体途径介导的细胞凋亡;因此,Antitumor agent-122 可用于胃癌、肝癌、卵巢癌、膀胱癌等实体瘤的研究。
产品编号: MS-L40523 CAS No.: 2378641-43-9 分子式: C28H30N4O2S2 分子量: 518.69
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Antitumor agent-122 是一种高效多靶点抗肿瘤剂,通过诱导铁死亡 (Ferroptosis)、自噬 (Autophagy)、凋亡 (Apoptosis) 和细胞周期阻滞 (Cell cycle arrest) 等机制发挥抗肿瘤作用:在铁死亡通路中,它可抑制 GPX4 表达并上调 FACL4 表达,增加细胞内脂质过氧化及亚铁离子水平;在自噬通路中,它通过抑制 AKT/mTOR 信号通路诱导自噬;在凋亡和细胞周期通路中,它将细胞阻滞于 G1/S 期,进而促进线粒体途径介导的细胞凋亡;因此,Antitumor agent-122 可用于胃癌、肝癌、卵巢癌、膀胱癌等实体瘤的研究。

生物实验数据

生物活性 Antitumor agent-122 is a highly potent multi-target antitumor agent that exerts its antitumor effects by inducing ferroptosis, autophagy, apoptosis, and cell cycle arrest: in the ferroptosis pathway, it inhibits GPX4 expression and upregulates FACL4 expression, thereby increasing intracellular lipid peroxidation and ferrous ion levels; in the autophagy pathway, it induces autophagy by inhibiting the AKT/mTOR signaling pathway; in the apoptosis and cell cycle pathways, it arrests cells at the G1/S phase and subsequently promotes mitochondria-mediated apoptosis; therefore, Antitumor agent-122 can be used for research on solid tumors such as gastric cancer, liver cancer, ovarian cancer, and bladder cancer.
IC50 & Target

GPX4

 

ACSL4

 

体外研究
(In Vitro)

Antitumor agent-122 (compound 5j) 抑制 MGC-803、HepG-2、SKOV-3 和 T24 细胞增殖,IC50 值分别为 5.23、3.60、1.43 和 3.03 μM,同时在正常 HK2 和 HUVEC 细胞中表现出较低的细胞毒性,IC50 值分别为 14.92 和 16.74 μM。
Antitumor agent-122 抑制 A549 和顺铂耐药 A549/DDP 细胞增殖,IC50 分别为 14.86 μM 和 12.86 μM,耐药因子为 0.87。
Antitumor agent-122 (5 μM;24 h) 在 T24 细胞中通过降低 GPX4 表达、升高 FACL4 表达,并促进脂质过氧化物、亚铁离子、超氧阴离子和 ROS 积累诱导铁死亡。
Antitumor agent-122 (5 μM;24 h 和 48 h) 在 T24 细胞中诱导铁死亡样线粒体形态改变和自噬小体形成。
Antitumor agent-122 (2-8 μM;24 h) 在 T24 细胞中通过上调 LC3B、降低 P62、抑制 AKT/mTOR 相关信号并激活 ERK 信号诱导自噬。
Antitumor agent-122 (1-5 μM;7 天) 减少 T24 细胞克隆形成。
Antitumor agent-122 (1-10 μM;0-48 h) 抑制 T24 细胞迁移,且其抗迁移作用可被 ERK 抑制剂 FR180204 (MS-Y38022) 减弱。
Antitumor agent-122 (2-8 μM;24 h) 在 T24 细胞中通过上调 cleaved-caspase 3、cleaved-PARP、Bax、Bak 和 Bad 的表达促进线粒体途径凋亡。

Western Blot Analysis

Cell Line: T24
Concentration: 5 μM
Incubation Time: 24 h
Result: Markedly decreased intracellular GPX4 levels and increased FACL4 expression.

Western Blot Analysis

Cell Line: T24
Concentration: 2, 5, 8 μM
Incubation Time: 24 h
Result: Upregulated LC3B and decreased P62, confirming autophagy induction. Decreased phosphorylated AKT1, AKT1 and mTOR expression, and induced ERK1/2 phosphorylation in a dose-dependent manner.
Upregulated cleaved-caspase 3, cleaved-PARP, Bax, Bak and Bad.

Cell Proliferation Assay

Cell Line: T24
Concentration: 1, 2, 3, 4, 5 μM
Incubation Time: 7 days
Result: Reduced colony formation at different concentrations.

Cell Migration Assay

Cell Line: T24
Concentration: 1, 5, 7, 10 μM; FR180204 at 1, 2, 3 μM
Incubation Time: 0, 24, 48 h
Result: Inhibited T24 cell migration in a time- and concentration-dependent manner. Co-incubation with ERK inhibitor FR180204 (MS-Y38022) reduced the antimigratory effect.

Cell Cycle Analysis

Cell Line: T24
Concentration: 2, 5, 8 μM
Incubation Time: 24 h
Result: Induced G1/S cell cycle arrest in a concentration-dependent manner. The result was consistent with omics analysis and indicated cell cycle blockade after treatment.
Upregulated p21 and downregulated MCM5.
体内研究
(In Vivo)

Antitumor agent-122 (compound 5j) (5、15 mg/kg;腹腔注射;每 2 天一次;连续 21 天) 在 T24 裸鼠皮下移植瘤模型中具有抗肿瘤活性。
Antitumor agent-122 (5、15 mg/kg;腹腔注射;每 2 天一次;连续 21 天) 在 HepG-2 裸鼠皮下移植瘤模型中具有抗肿瘤活性且毒性有限。
Antitumor agent-122 (5、15 mg/kg;腹腔注射;每 2 天一次;持续 21天) 在 SKOV-3 荷瘤裸鼠模型中具有抗肿瘤活性。

Animal Model: T24 xenograft nude mouse model
Dosage: 5, 15 mg/kg
Administration: Intraperitoneal injection (i.p.); once every two days; for 21 days
Result: Suppressed T24 xenograft tumor growth. At 15 mg/kg, achieved a tumor inhibition ratio (TIR) of 56.3%, exceeding the effective antitumor threshold of 40%.
Showed lower antitumor activity in the low-dose group than in the high-dose group, indicating a dose-dependent effect.
Did not cause obvious severe body weight loss during treatment, suggesting acceptable tolerability.
Animal Model: HepG-2 xenograft nude mouse model
Dosage: 5, 15 mg/kg
Administration: Intraperitoneal injection (i.p.); once every two days; for 21 days
Result: Suppressed HepG-2 xenograft tumor growth. At 15 mg/kg, achieved a TIR of 50.0%, indicating effective in vivo antitumor activity.
Showed lower antitumor activity in the low-dose group than in the high-dose group.
Reduced tumor volume and tumor weight compared with vehicle group.
Showed less tissue toxicity than amonafide in heart, liver, spleen and lung pathological sections.
Animal Model: SKOV-3 xenograft nude mouse model
Dosage: 5, 15 mg/kg
Administration: Intraperitoneal injection (i.p.); once every two days; for 21 days
Result: Exhibited antitumor activity in SKOV-3 xenograft model.
Showed significantly less toxicity than amonafide in heart, liver, spleen and lung pathological sections, with the lowest comprehensive toxicity among all tested compounds, and was thus selected for further mechanistic investigation.

化学信息

分子量 518.69
分子式 C28H30N4O2S2
CAS No. 2378641-43-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础